Sernova Biotherapeutics
corporate_fare Company Profile
Sernova Biotherapeutics (OTC:SEOVF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 4 items for SEOVF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-05, rated 7/10. Across its 4 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above.
Recent high-impact activity:
- Sernova-Seraxis Close $11.2M Financing, Exceeding Target, to Fund Merger and Phase 1/2 Diabetes Trial
- Sernova and Seraxis Merge to Form BetaNova, Targeting Type 1 Diabetes Cell Therapy
- Sernova's Autologous Islet Transplant Therapy Gets FDA Orphan Drug Designation
- Sernova Secures $7.1M in Financing, Plans to Retire $17M Debt to Strengthen Balance Sheet
Short Interest & Short Volume
1.29 days to coverFINRA reported short interest of 56,877 shares in SEOVF as of the October 30, 2026 settlement, a 41.9% decrease from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 100.0% of SEOVF volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.